Open company graph database — free web & API
Login

Eisai (Suzhou) Trading Co., Ltd.

EisaiAliasエーザイ(蘇州)貿易有限公司Alias
Ticker
—
Listed market
—
Country
China
Employees (non-consolidated)
—
Related companies
13
§01

Basic information

BASIC
Head office
No.168, Xingpu Road, Suzhou Industrial Park, Suzhou
Chief executive
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

2
PharmaceuticalsMedical products distribution
§04

Related companies

13 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Eisai (Liaoning) Pharmaceutical Co., Ltd.
Group
Eisai China Inc.
Group
Eisai China Inc.
Group Customer
Suzhou Factory
Group
Unlimit Health Limited
Group
Arteryex Corporation
Customer
Econavista
Customer
Eisai America, Inc.
Customer
Eisai Innovation, Inc.
Customer
Eisai Korea Inc.
Customer
Wei Cai Pharmaceuticals Co., Ltd.
Customer
HI-Eisai Pharmaceutical, Inc.
Customer
Limited Liability Company Eisai
Customer
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

73 EVENTS

Eisai's founder, Toyoji Naito, is born on August 15 in Ito, Fukui, Japan.Sources

Toyoji leaves his village at age 15, heading west to find employment in Osaka.Sources

Toyoji is employed at Winkel Shokai in Kobe, taking night courses in foreign languages and bookkeeping.Sources

Toyoji leaves Winkel Shokai after being drafted into the Japanese Imperial Guard.Sources

After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe.Sources

World War I begins.Sources

Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd.Sources

Toyoji embarks on a seven-month business tour of India and Southeast Asia.Sources

World War I ends.Sources

Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil Castalol and analgesic cream Salomethyl.Sources

The Great Kanto Earthquake strikes, causing Tanabe Motosaburo Store Co., Ltd. to fall on hard times, including the main store in Tokyo burning down.Sources

Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, Animasa. Toyoji coins the term for 'high blood pressure' in its ad campaign.Sources

A Salomethyl newspaper ad created by Toyoji wins the Best Advertisement Award in Japan's Society for the Promotion of Newspaper Advertising.Sources

Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo.Sources

Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States.Sources

Nihon Eisai is established, focusing on in-house R&D to create new medicines.Sources

Sakuragaoka Laboratory Co., Ltd. launches vitamin E product Juvela and Japan's first sanitary tampon Sampon.Sources

World War II begins.Sources

Nihon Eisai Co., Ltd., the predecessor of Eisai, is established in Saitama.Sources

Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge under the name Nihon Eisai Co., Ltd.Sources

World War II ends.Sources

Nihon Eisai Co., Ltd.'s contraceptive suppository Sampoon receives official approval from the Japanese government.Sources

Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product Chocola BB Tablets and motion sickness remedy Travelmin.Sources

The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd.Sources

Eisai rolls out its first three-year mid-term plan. Its Head Office building in Tokyo is completed.Sources

Eisai opens its Taipei Office in Taiwan and is listed on the Tokyo and Osaka Stock Exchanges.Sources

Toyoji Naito receives the Japan Marketing Award. The Tokyo Olympics take place.Sources

The Kawashima Plant in Gifu is completed. Toyoji Naito is appointed chairman, Yuji Naito as president, and a three-tier director system is introduced.Sources

Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.Sources

PT Eisai Indonesia is established as a manufacturing and sales subsidiary in Indonesia.Sources

Toyoji Naito opens the Naito Museum of Pharmaceutical Science and Industry in Gifu.Sources

The first oil crisis occurs due to conflict in the Middle East.Sources

Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established. Neuquinon is launched in Japan.Sources

Juvelux, a vitamin E product, is launched in Japan.Sources

Founder Toyoji Naito passes away at age 89.Sources

Eisai Asia Regional Services Pte. Ltd. is established in Singapore.Sources

Eisai U.S.A. Inc. is established in California, and the Misato Plant begins pharmaceutical manufacturing in Saitama.Sources

The Tsukuba Research Laboratories open in Ibaraki.Sources

Eisai Chemical Co., Ltd. (now Kashima Plant) is established in Ibaraki for API manufacturing.Sources

Gastritis and gastric ulcer treatment Selbex is launched in Japan.Sources

Eisai supports healthcare awards and establishes the Boston Research Institute in Massachusetts.Sources

President Yuji Naito steps down, Haruo Naito becomes president; Eisai America and Europe subsidiaries are established.Sources

Eisai Machinery GmbH in Germany and Eisai (Thailand) Marketing Co., Ltd. are established.Sources

Eisai London Research Laboratories is established; Japan's bubble economy bursts.Sources

Eisai Hong Kong Co., Ltd. and Beijing Representative Office are established; Shenyang joint venture is formed; Eisai celebrates 50th anniversary.Sources

Eisai adopts current mission and objectives; Eisai Corporation of North America is established.Sources

Eisai Inc. in the US, Eisai Ltd. in the UK, and Eisai Deutschland GmbH in Germany are established.Sources

Eisai S.A. in France and Eisai Suzhou Pharmaceutical Co., Ltd. in China are established.Sources

KAN Research Institute in Osaka, Eisai Korea Inc., and North Carolina Plant are established; Aricept and Pariet launched internationally.Sources

Aricept launched in France; Pariet launched in Germany and UK.Sources

Pariet launched as AcipHex in the US; Aricept launched in Japan.Sources

The 9/11 terrorist attacks occur; Eisai Farmacéutica S.A. established in Madrid.Sources

Eisai Medical Research Inc. established; adopts 'Company with Committees' system.Sources

Eisai Europe Ltd. established in London; Eisai Pharmaceuticals India Pvt. Ltd. in Mumbai.Sources

Eisai S.r.l. in Italy, Pharma AG in Switzerland, and other subsidiaries established; Yuji Naito passes away.Sources

Eisai launches 'Dramatic Leap Plan'; new subsidiaries in Australia, Singapore, Portugal, and others established.Sources

Eisai Manufacturing Ltd. established in UK; acquires Morphotek Inc. in US; new subsidiaries in India and Belgium.Sources

Eisai acquires MGI Pharma; launches Humira in Japan.Sources

Eisai establishes subsidiaries in Austria and UK; opens European Knowledge Centre; launches Equfina in Japan.Sources

Eisai establishes subsidiaries in Canada and China; launches Halaven in US; signs WHO agreement.Sources

Great East Japan Earthquake; launches sixth mid-term plan 'HAYABUSA'; establishes subsidiaries in Brazil and Mexico.Sources

Signs London Declaration; launches Fycompa in Europe; Naito appointed FPMAJ president.Sources

Establishes LLC in Moscow; co-establishes GHIT Fund; provides free lymphatic filariasis medicine to WHO.Sources

Fycompa launched in US; Eisai China Holdings Ltd. established.Sources

Lenvima launched in US, Japan, Europe; acquires Liaoning Tianyi Pharmaceutical.Sources

Eisai launches 'EWAY2025'; establishes EA Pharma; launches Fycompa in Japan.Sources

Joins partnership for NCDs; supports lymphatic filariasis elimination; collaborates with Biogen on Alzheimer's treatments.Sources

Strategic collaboration for Lenvima with Merck; new Suzhou plant operational; Lenvima launched in China.Sources

Eisai G2D2 in Massachusetts begins operation; launches Equfina in Japan; launches Fycompa and Halaven in China.Sources

WHO declares COVID-19 a pandemic; launches brain health tool NouKNOW; DAYVIGO in US and Japan; establishes Vietnam subsidiary and Shanghai health company.Sources

Launch of eighth mid-term plan 'EWAY Future & Beyond'; ADUHELM approved and launched in US; enters collaboration with Bristol-Myers Squibb; celebrates 80th anniversary.Sources

Amends ADUHELM collaboration; makes Arteryex subsidiary; establishes subsidiaries in South Africa; signs Kigali Declaration; launches DHBL R&D organization.Sources

LEQEMBI granted accelerated and traditional FDA approval; funds third phase of GHIT; establishes Theoria Technologies in Tokyo; launches LEQEMBI in Japan.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑